Antisense Oligonucleotide Eluforsen Improves CFTR Function in F508del Cystic Fibrosis

Overview

Journal J Cyst Fibros

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2018 Nov 24

PMID 30467074

Citations 28

Authors

Isabelle Sermet-Gaudelus

John P Clancy

David P Nichols

Jerry A Nick

Kris De Boeck

George M Solomon

Marcus A Mall

James Bolognese

Florilene Bouisset

Wilhelmina den Hollander

Nicolas Paquette-Lamontagne

Nigel Tomkinson

Noreen Henig

J Stuart Elborn

Steven M Rowe

Affiliations

Soon will be listed here.

Abstract

Background: Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. In this study we assessed the effect of antisense oligonucleotide eluforsen on CFTR biological activity measured by Nasal Potential Difference (NPD) in patients with the most common mutation, F508del-CFTR.

Methods: This multi-centre, exploratory, open-label study recruited adults with CF homozygous or compound heterozygous for the F508del-CFTR mutation. Subjects received intranasal eluforsen three times weekly for 4 weeks. The primary endpoint was the within-subject change from baseline in total chloride transport (Cl-free+iso), as assessed by NPD. Secondary endpoints included within-subject change from baseline in sodium transport.

Results: In the homozygous cohort (n = 7; per-protocol population), mean change (90% confidence interval) in Cl-free+iso was -3.0 mV (-6.6; 0.6) at day 15, -4.1 mV (-7.8; -0.4, p = .04) at day 26 (end of treatment) and - 3.7 mV (-8.0; 0.6) at day 47. This was supported by improved sodium transport as assessed by an increase in average basal potential difference at day 26 of +9.4 mV (1.1; 17.7, p = .04). The compound heterozygous cohort (n = 7) did not show improved chloride or sodium transport NPD values. Eluforsen was well tolerated with a favourable safety profile.

Conclusions: In F508del-CFTR homozygous subjects, repeated intranasal administration of eluforsen improved CFTR activity as measured by NPD, an encouraging indicator of biological activity.

Citing Articles

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.

Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B Signal Transduct Target Ther. 2025; 10(1):73.

PMID: 40059188 PMC: 11891339. DOI: 10.1038/s41392-024-02112-8.

Cystic fibrosis management in pediatric population-from clinical features to personalized therapy.

Azoicai A, Lupu A, Trandafir L, Alexoae M, Alecsa M, Starcea I Front Pediatr. 2024; 12:1393193.

PMID: 38798310 PMC: 11116730. DOI: 10.3389/fped.2024.1393193.

Unlocking the potential of RNA-based therapeutics in the lung: current status and future directions.

Man H, Moosa V, Singh A, Wu L, Granton J, Juvet S Front Genet. 2023; 14:1281538.

PMID: 38075698 PMC: 10703483. DOI: 10.3389/fgene.2023.1281538.

RNA-based medicine: from molecular mechanisms to therapy.

Sparmann A, Vogel J EMBO J. 2023; 42(21):e114760.

PMID: 37728251 PMC: 10620767. DOI: 10.15252/embj.2023114760.

Gene Therapy for Cystic Fibrosis: Recent Advances and Future Prospects.

Lomunova M, Gershovich P Acta Naturae. 2023; 15(2):20-31.

PMID: 37538805 PMC: 10395777. DOI: 10.32607/actanaturae.11708.

References

Rowe S, Clancy J, Wilschanski M . Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol. 2011; 741:69-86. PMC: 3760477. DOI: 10.1007/978-1-61779-117-8_6. View

Stutts M, Canessa C, Olsen J, Hamrick M, Cohn J, Rossier B . CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995; 269(5225):847-50. DOI: 10.1126/science.7543698. View

Mehta A . CFTR: more than just a chloride channel. Pediatr Pulmonol. 2004; 39(4):292-8. DOI: 10.1002/ppul.20147. View

Kole R, Leppert B . Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy. Discov Med. 2012; 14(74):59-69. View

Finkel R, Chiriboga C, Vajsar J, Day J, Montes J, De Vivo D . Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016; 388(10063):3017-3026. DOI: 10.1016/S0140-6736(16)31408-8. View

Sheppard D, Welsh M . Structure and function of the CFTR chloride channel. Physiol Rev. 1999; 79(1 Suppl):S23-45. DOI: 10.1152/physrev.1999.79.1.S23. View

Mall M, Bleich M, Greger R, Schreiber R, Kunzelmann K . The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest. 1998; 102(1):15-21. PMC: 509060. DOI: 10.1172/JCI2729. View

Sermet-Gaudelus I, De Boeck K, Casimir G, Vermeulen F, Leal T, Mogenet A . Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med. 2010; 182(10):1262-72. DOI: 10.1164/rccm.201001-0137OC. View

Alton E, Armstrong D, Ashby D, Bayfield K, Bilton D, Bloomfield E . Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015; 3(9):684-691. PMC: 4673100. DOI: 10.1016/S2213-2600(15)00245-3. View

10.

Huang P, Gilmore E, Kultgen P, Barnes P, Milgram S, Stutts M . Local regulation of cystic fibrosis transmembrane regulator and epithelial sodium channel in airway epithelium. Proc Am Thorac Soc. 2005; 1(1):33-7. DOI: 10.1513/pats.2306012. View

11.

Alton E, Currie D, Warner J, Hodson M, Geddes D . Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J. 1990; 3(8):922-6. View

12.

Knowles M, GATZY J, Boucher R . Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med. 1981; 305(25):1489-95. DOI: 10.1056/NEJM198112173052502. View

13.

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

14.

Rowe S, Accurso F, Clancy J . Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc. 2007; 4(4):387-98. PMC: 2647604. DOI: 10.1513/pats.200703-043BR. View

15.

Rowe S, Liu B, Hill A, Hathorne H, Cohen M, Beamer J . Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One. 2013; 8(7):e66955. PMC: 3724869. DOI: 10.1371/journal.pone.0066955. View

16.

Vankeerberghen A, Cuppens H, Cassiman J . The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions. J Cyst Fibros. 2004; 1(1):13-29. DOI: 10.1016/s1569-1993(01)00003-0. View

17.

Mall M, Hartl D . CFTR: cystic fibrosis and beyond. Eur Respir J. 2014; 44(4):1042-54. DOI: 10.1183/09031936.00228013. View

18.

Ramsey B, Davies J, McElvaney N, Tullis E, Bell S, Drevinek P . A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18):1663-72. PMC: 3230303. DOI: 10.1056/NEJMoa1105185. View

19.

De Boeck K, Kent L, Davies J, Derichs N, Amaral M, Rowe S . CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J. 2012; 41(1):203-16. DOI: 10.1183/09031936.00057512. View

20.

Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M . Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008; 372(9640):719-27. DOI: 10.1016/S0140-6736(08)61168-X. View